Glioma Clinical Trial
Official title:
A Phase II Study of RAD001 (Everolimus) for Children With NeurF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas
The purpose of this research study is to learn if the study drug RAD001 can shrink or slow
the growth of low-grade gliomas in children with Neurofibromatosis type 1 (NF1).
Additionally, the safety of RAD001 will be studied.
The study drug, RAD001, is a drug that may act directly on tumor cells by preventing tumor
cell growth and development. RAD001 has been studied in participants with various types of
cancer as a single agent (a drug that is used alone to treat the cancer) or in combination
with a number of well known anticancer therapies. Information from these research studies
suggests that RAD001 may help to shrink or slow the growth of low-grade gliomas.
In this research study, the investigators are looking to see the response of RAD001 in
children with low-grade gliomas and NF1 that have either not responded to treatment or have
come back after treatment. We are also looking for the highest dose of RAD001 that can be
given safely in this patient population.
After signing this consent form, you will be asked to undergo some screening tests or
procedures to find out if you can be in the research study. These tests and procedures are
likely to be part of regular glioma care and may be done even if it turns out that you do not
take part in the research study. If you have had some of these tests or procedures recently,
they may or may not have to be repeated.
A medical history, which involves questions about your health history, any medications you
are taking or plan to take, and any allergies.
A physical exam, during which you will be asked about any problems that you might be having.
Additionally, your clinician will check your vital signs (body temperature, heart rate,
breathing rate, and blood pressure) and bodily systems (respiratory, nervous, digestive,
etc). The doctor will also evaluate your performance status, which indicates how much your
illness affects your activity level.
Blood tests, including tests to measure any effects of your disease. Approximately 1-2
teaspoons of blood will be drawn for these tests.
Urine test, which will be done to make sure your kidneys are functioning properly.
An assessment of your tumor using scans of the brain. MRI (Magnetic Resonance Imaging) will
be used to look at and evaluate the tumor.
An Electrocardiogram (ECG), which measures the electrical activity of your heart
A pregnancy test for females of childbearing potential. A small amount of blood (about half a
teaspoon) or urine will be drawn for this test.
If these tests show that you are eligible to participate in the research study, you will
begin the study treatment. If you do not meet the eligibility criteria, you will not be able
to participate in this research study.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04539574 -
An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors
|
N/A | |
| Enrolling by invitation |
NCT04461002 -
Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.
|
||
| Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
| Completed |
NCT03242824 -
The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma
|
Phase 2 | |
| Recruiting |
NCT04186832 -
Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy
|
N/A | |
| Completed |
NCT00424554 -
Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)
|
Phase 2 | |
| Recruiting |
NCT05968053 -
Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
|
||
| Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
| Completed |
NCT02805179 -
A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma
|
Phase 2 | |
| Terminated |
NCT04556929 -
Enhanced Detection in Glioma Excision
|
N/A | |
| Not yet recruiting |
NCT06408428 -
Glioma Intraoperative MicroElectroCorticoGraphy
|
N/A | |
| Recruiting |
NCT06043232 -
MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas
|
||
| Not yet recruiting |
NCT06043765 -
Reducing Cognitive Impairment in Glioma With Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training
|
N/A | |
| Not yet recruiting |
NCT05025969 -
Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours
|
||
| Completed |
NCT02978261 -
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas
|
Phase 1 | |
| Terminated |
NCT01502605 -
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
|
Phase 1 | |
| Completed |
NCT01836536 -
Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients
|
N/A | |
| Completed |
NCT01479686 -
iMRI Guided Resection in Cerebral Glioma Surgery
|
Phase 3 | |
| Completed |
NCT01212731 -
Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
|
||
| Withdrawn |
NCT00985036 -
Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients
|
N/A |